Rick Doblin is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit psychedelic pharmaceutical company, which he founded in 1986 and has grown from a one-man project to an international company. Today, MAPS designs or sponsors psychedelic psychotherapy drug development research in over a dozen countries and has raised more than $70 million in donations.

Doblin's professional goal is to help develop legal contexts for the safe uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic psychotherapist.

Doblin received his master's degree and PhD in public policy from the Kennedy School of Government at Harvard University, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his master’s thesis on a survey of oncologists about smoked marijuana versus the oral THC pill in nausea control for cancer patients. He was among the first group of practitioners certified by Dr. Stanislav Grof in Holotropic Breathwork.

Health, Healthcare, Futurism, Healthcare Policy, Fitness & Nutrition Experts, Nutrition, Mental Health, Business of Healthcare, Psychologists, Psychology, Psychological Safety, Pharmaceutical, Science, Research & Exploration, Research Scientist, PTSD, Veterans, TED, Business, Aspen Health Alternative Medicine,